ERBB2 and neoplasm: These high‐avidity bispecific antibodies induced negligible effects on in vivo tumour models expressing low levels of HER‐2 but successfully eradicated high‐expressing tumour lines, suggesting that normal tissues expressing HER‐2 at low levels may be avoided and toxicity minimised.